Nothing Special   »   [go: up one dir, main page]

AR096388A1 - Anticuerpos anti-ácido teicoico de pared y sus conjugados - Google Patents

Anticuerpos anti-ácido teicoico de pared y sus conjugados

Info

Publication number
AR096388A1
AR096388A1 ARP140102029A ARP140102029A AR096388A1 AR 096388 A1 AR096388 A1 AR 096388A1 AR P140102029 A ARP140102029 A AR P140102029A AR P140102029 A ARP140102029 A AR P140102029A AR 096388 A1 AR096388 A1 AR 096388A1
Authority
AR
Argentina
Prior art keywords
acid
conjugates
thetic
wall
wall anti
Prior art date
Application number
ARP140102029A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR096388A1 publication Critical patent/AR096388A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)

Abstract

Anticuerpos anti-ácido teicoico de pared y conjugados antibióticos de ellos, y métodos para su uso. Composición farmacéutica; ácido nucleico; célula; método para tratar una infección bacteriana; kit; intermediario.
ARP140102029A 2013-05-31 2014-05-22 Anticuerpos anti-ácido teicoico de pared y sus conjugados AR096388A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361829461P 2013-05-31 2013-05-31

Publications (1)

Publication Number Publication Date
AR096388A1 true AR096388A1 (es) 2015-12-30

Family

ID=50983181

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102029A AR096388A1 (es) 2013-05-31 2014-05-22 Anticuerpos anti-ácido teicoico de pared y sus conjugados

Country Status (4)

Country Link
US (1) US20140356375A1 (es)
AR (1) AR096388A1 (es)
MA (1) MA44550B1 (es)
TW (2) TWI692483B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3004161B1 (en) 2013-05-31 2019-10-02 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
NZ720743A (en) 2013-12-16 2021-12-24 Medimmune Ltd Peptidomimetic compounds and antibody-drug conjugates thereof
PE20161394A1 (es) 2013-12-16 2017-01-06 Genentech Inc Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco
CA2940140A1 (en) * 2014-02-19 2015-08-27 The Texas A&M University System Compositions for drug sensitization of parasites
MX2017007055A (es) * 2014-12-03 2017-11-08 Genentech Inc Conjugados de anticuerpo rifamicina anti-staphylococcus aureus y usos de estos.
TW201709934A (zh) 2015-06-15 2017-03-16 建南德克公司 抗體及免疫結合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
MX2018006218A (es) 2015-12-04 2018-09-05 Seattle Genetics Inc Conjugados de compuestos de tubulisina cuaternizada.
CA3012046C (en) * 2016-03-04 2020-11-10 Genentech, Inc. Process for the preparation of an antibody-rifamycin conjugate
WO2017156458A1 (en) * 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
MX2021007524A (es) 2018-12-21 2021-08-05 Regeneron Pharma Analogos de rifamicina y conjugados de farmaco-anticuerpo de los mismos.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514636A (ja) * 2002-12-02 2006-05-11 バイオシネクサス インコーポレーテッド 抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸
KR101192496B1 (ko) * 2003-11-06 2012-10-18 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물

Also Published As

Publication number Publication date
TW201524997A (zh) 2015-07-01
MA44550B1 (fr) 2021-06-30
TW201839012A (zh) 2018-11-01
TWI632157B (zh) 2018-08-11
US20140356375A1 (en) 2014-12-04
MA44550A1 (fr) 2019-06-28
TWI692483B (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
AR096388A1 (es) Anticuerpos anti-ácido teicoico de pared y sus conjugados
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
BR112015030946A8 (pt) composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa
AR094375A1 (es) Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
PE20160715A1 (es) Anticuerpos frente a acidos teicoicos de pared y conjugados
AR095774A1 (es) Anticuerpos anti-il-4 y anticuerpos biespecíficos y sus usos
AR089178A1 (es) Anticuerpos anti-il-36r
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
CL2015000582A1 (es) Anticuerpos anti-mcam y métodos asociados de uso
AR090017A1 (es) Agonistas de fgfr1 y sus metodos de uso
EP3026108A4 (en) Cell culturing method, cell culturing apparatus and kit
BR112013021134A2 (pt) moduladores e métodos de uso
CL2012002125A1 (es) Metodo para la purificacion de anticuerpos de una mezcla de proteina en un biorreactor; unidad operacional que se utiliza en el metodo antes descrito.
AU2014247175A8 (en) Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use
ZA201905674B (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
UY35510A (es) ?composiciones y métodos para mejorar la estabilidad microbiana?.
AR088322A1 (es) Anticuerpos anti-htra1 y metodos de uso
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
EA201491224A1 (ru) Анти-псф-тау-антитела и их применение
AR090923A1 (es) Anticuerpos anti-il-23

Legal Events

Date Code Title Description
FB Suspension of granting procedure